Cargando…

Personalized activity index, a new safety monitoring tool for multiple sclerosis clinical trials

BACKGROUND: An abnormal increase of contrast-enhancing lesion (CEL) counts on frequent MRIs is interpreted as a signal of potential worsening in multiple sclerosis (MS) clinical trials. We demonstrate the utility of the MR personalized activity index (MR-pax) to identify such increases. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yinshan, Kondo, Yumi, Traboulsee, Anthony, Li, David KB, Riddehough, Andrew, Petkau, A John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433340/ https://www.ncbi.nlm.nih.gov/pubmed/28607690 http://dx.doi.org/10.1177/2055217315577829

Ejemplares similares

Improving the clinical correlation of multiple sclerosis black hole volume change by paired-scan analysis()
por: Tam, Roger C., et al.
Publicado: (2012)

Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials
por: Traboulsee, A, et al.
Publicado: (2017)

Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica
por: Manogaran, Praveena, et al.
Publicado: (2016)

Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic
por: Jure Hunt, David, et al.
Publicado: (2020)

Machine learning in secondary progressive multiple sclerosis: an improved predictive model for short-term disability progression
por: Law, Marco TK, et al.
Publicado: (2019)

Multiple Sclerosis in Older Adults: The Clinical Profile and Impact of Interferon Beta Treatment
por: Shirani, Afsaneh, et al.
Publicado: (2015)

Accounting for uncertainty in training data to improve machine learning performance in predicting new disease activity in early multiple sclerosis
por: Tayyab, Maryam, et al.
Publicado: (2023)

Prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis
por: Traboulsee, Anthony L, et al.
Publicado: (2016)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

Evaluating the safety of β-interferons in MS: A series of nested case-control studies
por: de Jong, Hilda J.I., et al.
Publicado: (2017)

Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder
por: Combes, Anna J.E., et al.
Publicado: (2017)

Data fusion detects consistent relations between non-lesional white matter myelin, executive function, and clinical characteristics in multiple sclerosis
por: Baumeister, Tobias R., et al.
Publicado: (2019)

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
por: Coles, Alasdair J, et al.
Publicado: (2021)

Deep learning of joint myelin and T1w MRI features in normal-appearing brain tissue to distinguish between multiple sclerosis patients and healthy controls
por: Yoo, Youngjin, et al.
Publicado: (2017)

Polypharmacy and multiple sclerosis: A population-based study
por: Chertcoff, Anibal, et al.
Publicado: (2022)

Cervical cord myelin abnormality is associated with clinical disability in multiple sclerosis
por: Lee, Lisa Eunyoung, et al.
Publicado: (2021)

Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis
por: O'Muircheartaigh, Jonathan, et al.
Publicado: (2019)

Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases
por: Liang, Geoffrey, et al.
Publicado: (2022)

Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis
por: Bansback*, Nick, et al.
Publicado: (2021)

Productivity loss among people with early multiple sclerosis: A Canadian study
por: Rodriguez Llorian, Elisabet, et al.
Publicado: (2022)

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years
por: Confavreux, Christian, et al.
Publicado: (2012)

Employment status, productivity loss, and associated factors among people with multiple sclerosis
por: Rodriguez Llorian, Elisabet, et al.
Publicado: (2023)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Evaluation of Kappa Index as a Tool in the Diagnosis of Multiple Sclerosis: Implementation in Routine Screening Procedure
por: Sanz Diaz, Carmen Teresa, et al.
Publicado: (2021)

Cannabis-based product use in a multiple sclerosis cohort
por: Schabas, AJ, et al.
Publicado: (2019)

Management of Fatigue in Persons with Multiple Sclerosis
por: Khan, Fary, et al.
Publicado: (2014)

Personalized Diagnosis and Therapy for Multiple Sclerosis
por: Ramo-Tello, Cristina
Publicado: (2022)

Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients
por: Bansback, Nick, et al.
Publicado: (2019)

Personalized monitoring of ambulatory function with a smartphone 2-minute walk test in multiple sclerosis
por: Lam, Ka-Hoo, et al.
Publicado: (2023)

Both Stationary and Dynamic Functional Interhemispheric Connectivity Are Strongly Associated With Performance on Cognitive Tests in Multiple Sclerosis
por: Lin, Sue-Jin, et al.
Publicado: (2020)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Recommendations for the use of propensity score methods in multiple sclerosis research
por: Simoneau, Gabrielle, et al.
Publicado: (2022)

Monitoring the Redox Status in Multiple Sclerosis
por: Tanaka, Masaru, et al.
Publicado: (2020)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

Optical Coherence Tomography and Visual Evoked Potentials as Prognostic and Monitoring Tools in Progressive Multiple Sclerosis
por: Guerrieri, Simone, et al.
Publicado: (2021)

Sex and age differences in the Multiple Sclerosis prodrome
por: Yusuf, Fardowsa L. A., et al.
Publicado: (2022)

Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging
por: Kolind, Shannon, et al.
Publicado: (2023)

Psychoeducational Interventions for Caregivers of Persons With Multiple Sclerosis: Protocol for a Randomized Trial
por: Douglas, Sara L, et al.
Publicado: (2021)

Cortical morphology predicts placebo response in multiple sclerosis
por: Cherkasova, Mariya V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h134rdef2707ks54hllr95rspq